DE69133623D1 - Haltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung - Google Patents

Haltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung

Info

Publication number
DE69133623D1
DE69133623D1 DE69133623T DE69133623T DE69133623D1 DE 69133623 D1 DE69133623 D1 DE 69133623D1 DE 69133623 T DE69133623 T DE 69133623T DE 69133623 T DE69133623 T DE 69133623T DE 69133623 D1 DE69133623 D1 DE 69133623D1
Authority
DE
Germany
Prior art keywords
preparation
pharmaceutical formulations
new pharmaceutical
holding new
holding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69133623T
Other languages
English (en)
Inventor
Bengt Lindstedt
Per Johan Lundberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Semi Tech Design Inc
Original Assignee
Semi Tech Design Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Semi Tech Design Inc filed Critical Semi Tech Design Inc
Application granted granted Critical
Publication of DE69133623D1 publication Critical patent/DE69133623D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
DE69133623T 1990-12-07 1991-12-03 Haltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung Expired - Fee Related DE69133623D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9003903A SE9003903D0 (sv) 1990-12-07 1990-12-07 New pharmaceutical formulations
PCT/SE1991/000814 WO1992010171A1 (en) 1990-12-07 1991-12-03 New pharmaceutical formulations containing a pharmacologically active ionizable substance as well as process for the preparation thereof

Publications (1)

Publication Number Publication Date
DE69133623D1 true DE69133623D1 (de) 2009-11-19

Family

ID=20381122

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69133623T Expired - Fee Related DE69133623D1 (de) 1990-12-07 1991-12-03 Haltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung

Country Status (17)

Country Link
US (2) US5707656A (de)
EP (1) EP0560816B1 (de)
JP (1) JP3276956B2 (de)
AT (1) ATE444737T1 (de)
AU (1) AU656346B2 (de)
CA (1) CA2097176C (de)
DE (1) DE69133623D1 (de)
EE (1) EE03105B1 (de)
FI (1) FI932553A0 (de)
HU (1) HU218661B (de)
IE (1) IE914136A1 (de)
IS (1) IS1749B (de)
NO (1) NO305536B1 (de)
PT (1) PT99720B (de)
SE (1) SE9003903D0 (de)
WO (1) WO1992010171A1 (de)
YU (1) YU186791A (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0946145B1 (de) * 1996-12-20 2008-09-03 McNeil-PPC, Inc. Durch ionenaustauscherharze verabreichte hustenmittel
AU6381300A (en) * 1999-07-29 2001-02-19 Roxane Laboratories, Inc. Opioid sustained-released formulation
US20030118641A1 (en) * 2000-07-27 2003-06-26 Roxane Laboratories, Inc. Abuse-resistant sustained-release opioid formulation
EP2311460A1 (de) * 2001-07-06 2011-04-20 Endo Pharmaceuticals Inc. Kontrolliert freisetzende Formulierungen von Oxymorphon
US20030099711A1 (en) * 2001-08-29 2003-05-29 David Meadows Sustained release preparations
MXPA04009701A (es) * 2002-04-05 2005-05-27 Penwest Pharmaceuticals Co Formulaciones de metoprolol de liberacion sostenida.
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
US20050265955A1 (en) * 2004-05-28 2005-12-01 Mallinckrodt Inc. Sustained release preparations
JP2006296511A (ja) * 2005-04-15 2006-11-02 Transcutaneous Technologies Inc 外用剤、外用剤の塗布方法、イオントフォレーシス装置及び経皮パッチ
JP2006346368A (ja) * 2005-06-20 2006-12-28 Transcutaneous Technologies Inc イオントフォレーシス装置及びその製造方法
WO2007010900A1 (ja) * 2005-07-15 2007-01-25 Transcu Ltd. 貼付位置表示機能付き経皮吸収用パッチ及びイオントフォレーシス装置
JP2007037868A (ja) * 2005-08-05 2007-02-15 Transcutaneous Technologies Inc 経皮投与装置及びその制御方法
US8386030B2 (en) * 2005-08-08 2013-02-26 Tti Ellebeau, Inc. Iontophoresis device
US20070060860A1 (en) * 2005-08-18 2007-03-15 Transcutaneous Technologies Inc. Iontophoresis device
JPWO2007026671A1 (ja) * 2005-08-29 2009-03-05 Ｔｔｉ・エルビュー株式会社 センサからの情報により投与すべき薬剤の選定を行うイオントフォレーシス装置
US20090216177A1 (en) * 2005-09-16 2009-08-27 Tti Ellebeau,Inc Catheter-type iontophoresis device
US20070073212A1 (en) * 2005-09-28 2007-03-29 Takehiko Matsumura Iontophoresis apparatus and method to deliver active agents to biological interfaces
US20070071807A1 (en) * 2005-09-28 2007-03-29 Hidero Akiyama Capsule-type drug-releasing device and capsule-type drug-releasing device system
EP1944057A4 (de) * 2005-09-30 2009-02-18 Tti Ellebeau Inc Iontophorese-gerät zur kontrolle der dosis und zeit der verabreichung eines schlafinduzierenden und analeptischen mittels
BRPI0616771A2 (pt) * 2005-09-30 2011-06-28 Tti Ellebeau Inc dispositivo de iontoforese para liberar múltiplos agentes ativos para interfaces biológicas
US20090299265A1 (en) * 2005-09-30 2009-12-03 Tti Ellebeau, Inc. Electrode Assembly for Iontophoresis Having Shape-Memory Separator and Iontophoresis Device Using the Same
US20070197955A1 (en) * 2005-10-12 2007-08-23 Transcutaneous Technologies Inc. Mucous membrane adhesion-type iontophoresis device
US20080193514A1 (en) * 2006-11-02 2008-08-14 Transcu Ltd. Compostions and methods for iontophoresis delivery of active ingredients through hair follicles
JPWO2008087803A1 (ja) * 2007-01-16 2010-05-06 国立大学法人北海道大学 抗酸化成分を封入したイオントフォレーシス用リポソーム製剤
JP2010187707A (ja) * 2007-06-12 2010-09-02 Hokkaido Univ インスリンを封入したイオントフォレーシス用リポソーム製剤
CN102209573A (zh) * 2008-09-10 2011-10-05 透皮株式会社 将基于hpc的粘性液体分配至多孔基材中的设备和方法,例如基于连续匹的工艺
CA2757337A1 (en) * 2009-04-03 2010-10-07 Coating Place, Inc. Modified-release pharmaceutical drug composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4983392A (en) * 1983-11-14 1991-01-08 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US4692462A (en) * 1985-03-18 1987-09-08 Menley & James Laboratories, Ltd. Compositions and method of controlling transdermal penetration of topical and systemic agents
EP0199855A1 (de) * 1985-05-02 1986-11-05 Gist-Brocades N.V. Trimethoprim und ein Sulfonamid enthaltende Tabletten
JPS62223112A (ja) * 1986-03-25 1987-10-01 Rooto Seiyaku Kk 歯周病治療剤
IE62100B1 (en) * 1986-07-30 1994-12-14 Fisons Corp Coated ion exchange resins
DE3740684A1 (de) * 1987-12-01 1989-06-15 Woehr Otto Gmbh Parksystem
MC2025A1 (fr) * 1988-04-20 1990-04-25 Asta Pharma Ag Medicament contenant de l'azelastine et capable de liberer celle-ci de facon controlee
IL90245A (en) * 1988-05-11 1994-04-12 Glaxo Group Ltd Resin adsorption containing ranitidine together with synthetic resin replaces cations, its preparation and pharmaceutical preparations containing it
CA2002492A1 (en) * 1988-11-11 1990-05-11 Sandra T. A. Malkowska Pharmaceutical ion exchange resin composition
US5149523A (en) * 1989-06-20 1992-09-22 Aktiebolaget Hassle Polystyrenesulfonate-drug complex and solid dosage forms thereof

Also Published As

Publication number Publication date
JPH06503311A (ja) 1994-04-14
AU656346B2 (en) 1995-02-02
IE914136A1 (en) 1992-06-17
NO305536B1 (no) 1999-06-21
FI932553A (fi) 1993-06-04
CA2097176C (en) 2002-03-26
PT99720B (pt) 2002-04-29
IS1749B (is) 2000-07-11
JP3276956B2 (ja) 2002-04-22
NO932053L (no) 1993-07-20
NO932053D0 (no) 1993-06-04
YU186791A (sh) 1994-04-05
EE03105B1 (et) 1998-08-17
EP0560816B1 (de) 2009-10-07
SE9003903D0 (sv) 1990-12-07
WO1992010171A1 (en) 1992-06-25
US5707656A (en) 1998-01-13
AU8930591A (en) 1992-07-08
US5709882A (en) 1998-01-20
IS3787A7 (is) 1992-06-08
CA2097176A1 (en) 1992-06-08
PT99720A (pt) 1992-10-30
FI932553A0 (fi) 1993-06-04
HU218661B (hu) 2000-10-28
EP0560816A1 (de) 1993-09-22
ATE444737T1 (de) 2009-10-15
HUT64213A (en) 1993-12-28
HU9301671D0 (en) 1993-09-28

Similar Documents

Publication Publication Date Title
DE69133623D1 (de) Haltende neue pharmazeutische formulierungen sowie verfahren zu deren herstellung
ATA84882A (de) Therapeutisches abgabesystem zur verabreichung eines wirkstoffes durch die haut
BR9406363A (pt) Composiçao farmacêutica processo para a preparaçao da mesma uso da mesma e processo para o tratamento de doenças relacionadas com o ácido gástrico
DK0436370T3 (da) Farmaceutisk præparat til kontrolleret afgivelse og fremgangsmåde til fremstilling deraf
ATE50989T1 (de) Gewisse 3-amino-1-benzazepin-2-on-1-alkansaeuren, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
PT1035834E (pt) Forma de dosagem osmotica que compreende primeiro e segundo revestimentos
DK0395329T3 (da) Sammensætning i form af et skum indeholdende 5-aminosalicylsyre til intrarektal administration
ATE56365T1 (de) Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung.
ATA293589A (de) Neue chinolinsulfonaminoderivate und verfahren zu deren herstellung sowie pharmazeutische zusammensetzung
DE3863366D1 (de) Antibiotikum vermisporin, verfahren zu dessen herstellung und dasselbe als aktiver antibakterieller wirkstoff enthaltende pharmazeutische zusammensetzung.
DE68901771D1 (de) Phospholipid enthaltende zusammensetzung, verfahren zu deren herstellung und verwendung als hilfsstoff fuer pharmazeutische substanzen.
DK0957981T3 (da) Rersorvoirer til aflevering af lægemidler ved elektrotransport, indeholdende inerte fyldmaterialer
ATE15196T1 (de) N-substituierte 2-pyridylindole, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
ATE61522T1 (de) Pharmazeutische zubereitung zur behandlung von tinea pedis.
DE68906461T2 (de) Feste Arzneidosis in Form eines Tablettentriturats sowie Verfahren zu deren Herstellung.
ES2040891T3 (es) Nuevo sistema plastificante hidrofilo y goma de mascar que contiene el mismo.
DE69529079D1 (de) Codein enthaltende formulierungen
DE69803772T2 (de) Oral anzuwendende feste arzneizubereitungen mit modulierter wirkstoffabgabe enthaltend nicorandil und verfahren zu deren herstellung
LU84492A1 (de) Cumarin-derivate,verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische praeparate
ATE81586T1 (de) Arzneiformulierung zur transdermalen absorption des wirkstoffs sowie verfahren zu deren herstellung.
ATE77034T1 (de) Phospholipid enthaltende zusammensetzung, verfahren zu deren herstellung und verwendung als hilfsstoff fuer pharmazeutische substanzen.
ATE36320T1 (de) Beta-oxo-alpha-carbamoyl-pyrrolpropionitrile, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
PT69963A (de) Alpha-alkylaminoalkyl-hydroxy-benzylalkohole verfahren zu ihrer herstellung pharmazeutische praparate enthaltend diese verbindungen sowie ihre therapeutische verwendung
DE3875460D1 (de) Arzneiformulierung zur transdermalen absorption des wirkstoffs sowie verfahren zu deren herstellung.
ATE10933T1 (de) Neues peptid, verfahren zu dessen herstellung und pharmazeutische zusammensetzung.

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee